Clinical trial · Interventional
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia. Patients receive one year of intensive cyclical chemotherapy with additional prophylaxis for central nervous system (CNS) relapse by intrathecal therapy and cranial irradiation and mediastinal irradiation after induction chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Lymphoblastic | Lymphoblastic Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (17)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adriamycin | Drug | — | UNRESOLVED |
| Asparaginase | Drug | Asparaginase | ALIAS |
| Cladribine | Drug | Cladribine | ALIAS |
| CNS irradiation | Procedure | — | UNRESOLVED |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
| Dexamethasone/Prednisolone | Drug | — | UNRESOLVED |
| G-CSF |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- remission rate, remission duration, disease free survival, overall survival
Secondary outcomes (1)
- measure
- time and dose compliance, toxicity according to World Health Organization (WHO)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * T-lymphoblastic lymphoma (bone marrow \[BM\] involvement \< 25%) * Aged 15-65 years (55-65 years if biologically younger) * Written informed consent Exclusion Criteria: * Severe complications due to lymphoma or secondary disease * T-LBL as second malignancy or other active second malignancy * Cytostatic pretreatment of LBL (exception of emergency treatments) * Pregnancy * Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent * Participation in other study interfering with study treatment
References
Publications (0)
Data not yet available